SCHEMBL5222854

SCHEMBL5222854

CC(C)C(=O)C(NC(=O)c1ccc(Cl)cc1)C(=O)NCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
RAB9A P51151 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
GPR139 Q6DWJ6 1/20 0.47
TSHR P16473 1/20 0.47
LMNA P02545 3/20 0.47
HTT P42858 3/20 0.47
EPHX2 P34913 1/20 0.46
PPARG P37231 1/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
ADAMTS4 O75173 1/20 0.46
ADAMTS5 Q9UNA0 1/20 0.46
ALDH1A1 P00352 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5223536 0.88 NPC1 (0.51) KMT2AMEN1RAB9ASMN1; SMN2LMNA
SCHEMBL5226231 0.77 HDAC6 (0.72) KMT2AMEN1RAB9ASMN1; SMN2LMNA
SCHEMBL5225540 0.73 HTT (0.50) KMT2AMEN1RAB9ASMN1; SMN2LMNA
SCHEMBL8310068 0.72 MEN1 (0.63) KMT2AMEN1RAB9ASMN1; SMN2TSHR
SCHEMBL8760 0.72 KMT2A (0.67) KMT2AMEN1SMN1; SMN2CYP2C19ALDH1A1
SCHEMBL10769950 0.71 KMT2A (0.81) KMT2AMEN1RAB9ASMN1; SMN2TSHR
SCHEMBL3461078 0.71 HDAC6 (0.70) KMT2AMEN1RAB9ASMN1; SMN2TSHR
SCHEMBL8213132 0.71 SLC6A9 (0.60) KMT2AMEN1RAB9ASMN1; SMN2GPR139
SCHEMBL9354372 0.71 ADAMTS4 (0.64) KMT2AMEN1RAB9ASMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL23235729 0.70 KMT2A (0.65) KMT2AMEN1SMN1; SMN2CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740549-A2 NOVEL IMIDAZOLES Warner-Lambert Company LLC (US) 2007-01-10 EP disclosed
US-20060287378-A1 Novel pyrroles and imidazoles WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
WO-2005105079-A2 NOVEL IMIDAZOLES WARNER-LAMBERT COMPANY LLC (US) 2005-11-10 WO disclosed
US-20050239857-A1 Novel imidazoles BOLTON GARY L 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287378-A1 Novel pyrroles and imidazoles PPIP5K2, PPIE, PPOX KMT2A 3468/4885MEN1 1820/4885RAB9A 2152/4885
US-20050239857-A1 Novel imidazoles HMGCR, HMGB2, HMGB3 KMT2A 1257/4885MEN1 1778/4885RAB9A 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.